iCo Therapeutics Inc  

(Public, CVE:ICO)   Watch this stock  
Find more results for cve:ico
0.0300
0.0000 (0.00%)
Dec 17 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.03 - 0.04
52 week 0.03 - 0.59
Open 0.04
Vol / Avg. 712,500.00/231,902.00
Mkt cap 2.53M
P/E     -
Div/yield     -
EPS -0.05
Shares 84.46M
Beta 0.50
Inst. own     -
Nov 28, 2014
Q3 2014 iCo Therapeutics Inc Earnings Release
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -13.40% -163.29%
Return on average equity -18.77% -338.57%
Employees 5 -
CDP Score - -

Address

760-777 Hornby Street
VANCOUVER, BC V6Z 1S4
Canada
+1-604-6029414 (Phone)
+1-604-6029699 (Fax)

Website links

Description

iCo Therapeutics Inc. is a development stage pharmaceutical company. The Company is focused on the reprofiling and repositioning of drugs and drug candidates with a previous clinical history for new disease indications. The Company is developing iCo-007, a second generation antisense inhibitor targeting C-raf kinase messenger ribonucleic acid (mRNA), for the treatment of retinal neovascular diseases such as diabetic retinopathy (including diabetic macular edema). The iCo-008 (also known as Bertilimumab or CAT-213) is a human immunoglobulin monoclonal antibody targeting eotaxin-1, a member of the chemokine family of proteins that acts as messenger molecules between the cells of the immune system. The Company owns the worldwide exclusive rights to an oral Amphotericin B delivery system for life-threatening infections.

Officers and directors

William W. Jarosz J.D. Independent Chairman of the Board
Andrew J Rae President, Chief Executive Officer, Director
W. John Meekison Chief Financial Officer, Corporate Secretary
Peter Hnik M.D. Chief Medical Officer
Age: 51
Richard W. Barker OBE Independent Director
Age: 65
Noel F. Hall Independent Director
Age: 45
Douglas G. Janzen Independent Director
Age: 41